Monday, November 5, 2012
Regulus Gets $80.9M In Financing Efforts
La Jolla-based biopharmaceuticals firm Regulus Therapeutics, which is developing microRNA-based biopharmaceuticals aimed at oncology, fibrosis, hepatitis C and metabolic diseases, said it has raised $80.9M in total proceeds from its IPO, a private placement, and convertible note. The firm said $50.9M came from its sale of common stock, $25.0M in a private placement to AstraZeneca AB, and $5.0M from a convertible note sale to Biogen Idec. The firm said those funds will enable it to "executive its current strategic objectives" for the foreseeable future.